The clinical success of immune checkpoint inhibitors for treating multiple cancer types has driven interest in streamlining the development of existing and novel checkpoint inhibitor therapies. To facilitate the large-scale screening of these compounds, we generated reporter cancer cell lines that have high endogenous expression of immune checkpoint molecules (PD-L1, CD155, and B7-H3). These reporter cell lines produce a robust, bioluminescent signal upon checkpoint blockade that can be quantified to evaluate the efficacy, potency, and dynamics of the checkpoint inhibitor. In this webinar, ATCC scientists discuss the application of these novel reporter cell lines in gamma interferon stimulation assays and immune cell co-culture assays and share insights on how these cell lines can be adopted into checkpoint reporter assay workflows.
